• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

98.90 -2.96 (-2.91%)
Streaming Delayed Price Updated: 2:43 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
The Great Divergence: Why Big Tech Holds the Line While Logistics and Biotech Face a 2026 Reckoning
December 30, 2025
As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
December 30, 2025
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three... 
Via MarketMinute
Topics ETFs Economy World Trade
News headline image
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗
December 11, 2025
The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management. 
Via Stocktwits
News headline image
Earnings Scheduled For November 4, 2025 ↗
November 04, 2025
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals's Earnings: A Preview ↗
November 03, 2025
 
Via Benzinga
News headline image
Earnings Scheduled For August 5, 2025 ↗
August 05, 2025
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
December 11, 2025
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
December 11, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
December 10, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
December 10, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's after hours session ↗
November 11, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
November 10, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million ↗
November 08, 2025
Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
November 07, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
November 05, 2025
IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB 
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reports Mixed Q3 2025 Results ↗
November 04, 2025
Rhythm Pharmaceuticals posts mixed Q3 2025 results, missing revenue estimates. Despite the loss, the company highlights strong drug growth and key regulatory milestones for its obesity treatments. 
Via Chartmill
News headline image
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
November 04, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
October 27, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 21, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Under-the-Radar Stocks That Could Soar ↗
September 21, 2025
They could ride the wave of the hottest therapeutic area in the industry. 
Via The Motley Fool
News headline image
Peering Into Rhythm Pharmaceuticals's Recent Short Interest ↗
September 11, 2025
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
August 27, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
August 20, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Analysts Have This To Say About Rhythm Pharmaceuticals ↗
August 06, 2025
 
Via Benzinga
News headline image
Rhythm (RYTM) Q2 Revenue Jumps 67% ↗
August 05, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider Losses ↗
August 05, 2025
Rhythm Pharmaceuticals Q2 2025 results show revenue beat but EPS miss, causing a 5.7% pre-market drop. Regulatory progress for setmelanotide remains on track. 
Via Chartmill
News headline image
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
August 05, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
July 22, 2025
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Should You Invest in This Under-the-Radar Weight Loss Stock? ↗
July 21, 2025
Via The Motley Fool
News headline image
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts ↗
July 18, 2025
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap